All quotes are delayed by at least 15 minutes.
MarketGrader Top Down Analysis
Sector Analysis - MRK ranks 156 out of 577 stocks in the sector
Industry Analysis - MRK ranks 8 out of 29 stocks in the industry
| Merck & Co., Inc. |
Key Financials |
Relative to Peer Avg |
| Quarterly Revenue Growth |
-8.85% |
|
| Annual Revenue Growth |
38.30% |
|
| Quarterly Net Income Growth |
-8.34% |
|
| Annual Net Income Growth |
-48.85% |
|
| Quarterly Free Cash Flow Growth |
|
|
| Total Debt Relative to Total Capital |
30.13% |
|
| Operating Margin |
18.40% |
 Above |
| Return on Equity |
11.356% |
|
| Merck & Co., Inc. (MRK) Dilution Analysis |
| Latest EPS |
$0.52 |
EPS Loss From Dilution |
N/A |
Top Competitors
| Company |
Revenue* |
Net Income* |
Rating |
Sentiment |
| JNJ |
17,508.00 |
3,497.00 |
Sign up to view |
| NVS |
14,091.01 |
2,410.83 |
Sign up to view |
| PFE |
13,500.00 |
2,742.00 |
Sign up to view |
| MRK |
10,693.00 |
1,593.00 |
Sign up to view |
| SNY |
10,607.90 |
1,321.54 |
Sign up to view |
| GSK |
9,969.35 |
1,480.54 |
Sign up to view |
| AZN |
6,219.75 |
984.83 |
Sign up to view |
| LLY |
5,602.00 |
1,548.00 |
Sign up to view |
| BMY |
3,831.00 |
609.00 |
Sign up to view |
| NVO |
3,527.20 |
1,055.88 |
Sign up to view |
*Revenue and Net Income figures are based on latest quarterly financials.
Sign up for complete Sentiment Analysis
